Vaccine placebo

BIOLOGICAL2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

HIV Infections

Phase 2

Effectiveness of and Immune Response to HIV Vaccination Followed by Treatment Interruption in HIV Infected Patients

CompletedNCT00080106

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2004-06-30End: 2011-05-31Updated: 2021-11-09

Safety of and Immune Response to an HIV DNA Plasmid Vaccine Followed by HIV Adenoviral Vector Vaccine in Healthy African Adults

WithdrawnNCT00415649

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Updated: 2021-11-01

Related Papers

Relationship of HIV reservoir characteristics with immune status and viral rebound kinetics in an HIV therapeutic vaccine study

AIDS2014-09-2433 citations

Characteristics and outcomes of initial virologic suppressors during analytic treatment interruption in a therapeutic HIV-1 gag vaccine trial.

2012-03-306 citations

Factors associated with viral rebound in HIV-1-infected individuals enrolled in a therapeutic HIV-1 gag vaccine trial.

2011-04-0123 citations